Collaboration and License Agreements - Sarepta Therapeutics, Inc. Consideration Components (Details) - Sarepta - Sarepta Collaboration Agreement - USD ($) $ in Thousands				9 Months Ended
Feb. 14, 2025	Feb. 07, 2025	Nov. 25, 2024	Jun. 30, 2025
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment	$ 500,000			$ 500,000
Annual fees			$ 250,000	250,000
Equity premium		$ 83,600		83,612
Fixed consideration				833,612
Estimated variable consideration				71,243
Total transaction price				$ 904,855

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration